Home » AVANT ANNOUNCES START OF CLINICAL TRIAL OF TYPHOID FEVER VACCINE
AVANT ANNOUNCES START OF CLINICAL TRIAL OF TYPHOID FEVER VACCINE
Avant Immunotherapeutics has launched a placebo-controlled, double-blind Phase I/II study of its typhoid fever vaccine candidate, Ty800. The clinical trial, sponsored by the NIH, is being conducted at the Cincinnati Children's Hospital Medical Center.
The study is an in-patient dose-escalating clinical trial aimed at determining the safety and immunogenicity of the single-dose, oral Ty800 vaccine. The trial will evaluate three escalating dose levels of the vaccine, in approximately 54 healthy adult volunteers and will follow each subject for six months post-vaccination. The trial seeks to confirm the safety and immunogenicity of the Ty800 vaccine observed in an earlier physician-sponsored Ty800 vaccine study.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May